Ear Infection Treatment Market By Infection (Inner Ear, Middle Ear, Outer Ear), By Pathogen (Bacteria, Virus, Fungus), By Treatment (Drugs, Surgery), By End User (Hospitals, Clinics, Others): Global Opportunity Analysis & Industry Forecast, 2023-2032
귀 감염 치료 시장은 2022년 118억 달러로 평가되었고, 2023년부터 2032년까지 연평균 5.1% 성장하여 2032년에는 195억 달러에 이를 것으로 추정됩니다.
세계 귀 감염 치료 시장의 성장을 가속하는 주요 요인으로는 진단 도구 및 치료법의 급속한 기술 발전, 귀 감염의 유병률 증가로 귀 감염 치료 수요를 더욱 증가시키고 있습니다. 또한, 고령화로 인해 귀 감염을 포함한 다양한 건강 상태에 노출되기 쉽다. 세계 인구의 고령화에 따라 귀 감염 환자가 증가할 가능성이 높아져 귀 감염 치료제의 소비자 기반이 확대될 것입니다.
그러나 수술 합병증, 수술 비용 상승, 내성균의 출현 등이 귀 감염 치료 시장의 성장을 제한할 것으로 예상됩니다. 반면, 신흥국의 의료비 지출 급증과 더 나은 치료 옵션에 대한 미충족 의료 수요는 향후 세계 시장 확대에 유리한 기회를 창출할 것으로 예상됩니다.
귀 감염 치료 시장은 감염, 병원체, 치료법, 최종 사용자, 지역별로 세분화됩니다. 감염 기준으로 시장은 내이, 중이, 외이로 분류됩니다. 병원체별로 귀 감염 치료 시장은 박테리아, 바이러스 및 곰팡이로 분류됩니다. 치료 방법별로 귀 감염 치료 시장은 약물과 수술로 나뉩니다. 약물 부문은 항생제 치료, 진통제 및 기타로 나뉩니다. 최종 사용자별로 귀 감염 치료 시장은 병원, 클리닉, 기타로 나뉩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 개요
- 시장 정의와 범위
- 주요 조사 결과
- Porter의 Five Forces 분석
- 시장 역학
제4장 귀 감염 치료 시장 : 감염증별
제5장 귀 감염 치료 시장 : 병원체별
제6장 귀 감염 치료 시장 : 치료법별
제7장 귀 감염 치료 시장 : 최종사용자별
제8장 귀 감염 치료 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카/중동 및 아프리카
제9장 경쟁 구도
- 서론
- 주요 성공 전략
- 주요 10개 기업의 제품 매핑
- 경쟁 대시보드
- 경쟁 히트맵
- 주요 기업의 포지셔닝, 2022년
제10장 기업 개요
- WraSer pharmaceutical
- Torque Pharmaceuticals Pvt. Ltd.
- Glenmark Pharmaceuticals Limited
- Candela Healthcare Private Limited
- Leeford Healthcare Limited
- FDC Limited
- Torrent Pharmaceuticals Ltd.
- Novartis AG
- Cipla Ltd.
- SUN PHARMACEUTICAL INDUSTRIES LIMITED
LSH
According to a new report published by Allied Market Research, titled, "Ear Infection Treatment Market," The ear infection treatment market was valued at $11.8 billion in 2022, and is estimated to reach $19.5 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.
Major factors that drive the growth of the global ear infection treatment market include rapid technological advancements in diagnostic tools & treatment methods and increase in prevalence of ear infections, which further increase the demand for ear infection treatment drugs. In addition, the aging population is more susceptible to various health conditions, including ear infections. As the global population ages, there is a higher likelihood of increased ear infection cases, creating a larger consumer base for ear infection treatments.
However, complications of surgery, high cost of surgery, and emergence of bacterial resistance are expected to restrict the growth of the ear infection treatment market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are anticipated to create lucrative opportunities for the expansion of the global market in the future.
The ear infection treatment market is segmented on the basis of infection, pathogen, treatment, end user, and region. On the basis of infection, the market is classified into the inner ear, middle ear, and outer ear. By pathogen, the ear infection treatment market is categorized into bacteria, virus, and fungus. By treatment, the ear infection treatment market is divided into drugs, and surgery. The drugs segment is bifurcated into antibiotic therapy, pain medication, and others. On the basis of end user, the ear infection treatment market is segregated into hospitals, clinics, and others.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Candela Healthcare Private Limited, Cipla Ltd, FDC Limited, Glenmark Pharmaceuticals Limited, Leeford Healthcare Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd., Torque Pharmaceuticals Pvt. Ltd., Torrent Pharmaceuticals, WraSer Pharmaceuticals. These major players have adopted agreement as key developmental strategy to improve the product portfolio of the ear infection treatment market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ear infection treatment market analysis from 2022 to 2032 to identify the prevailing ear infection treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ear infection treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ear infection treatment market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)
- Go To Market Strategy
- Market share analysis of players by products/segments
- New Product Development/ Product Matrix of Key Players
- Average Selling Price Analysis / Price Point Analysis
- Brands Share Analysis
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By End User
By Infection
- Middle Ear
- Outer Ear
- Inner Ear
By Pathogen
By Treatment
- Drugs
- Drug Class
- Antibiotic Therapy
- Pain Medication
- Others
- Surgery
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Torque Pharmaceuticals Pvt. Ltd.
- FDC Limited
- Glenmark Pharmaceuticals Limited
- Torrent Pharmaceuticals Ltd.
- Leeford Healthcare Limited
- Novartis AG
- Cipla Ltd.
- SUN PHARMACEUTICAL INDUSTRIES LIMITED
- Candela Healthcare Private Limited
- WraSer pharmaceutical
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of ear infection
- 3.4.1.2. Rising awareness regarding ear infection treatment
- 3.4.2. Restraints
- 3.4.2.1. Emergence of bacterial resistance
- 3.4.3. Opportunities
- 3.4.3.1. High growth potential in developing countries
CHAPTER 4: EAR INFECTION TREATMENT MARKET, BY INFECTION
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Inner Ear
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Middle Ear
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Outer Ear
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
CHAPTER 5: EAR INFECTION TREATMENT MARKET, BY PATHOGEN
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Bacteria
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Virus
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Fungus
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
CHAPTER 6: EAR INFECTION TREATMENT MARKET, BY TREATMENT
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Drugs
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.2.4. Drugs Ear Infection Treatment Market by Drug Class
- 6.3. Surgery
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
CHAPTER 7: EAR INFECTION TREATMENT MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Hospitals
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Clinics
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- 7.4. Others
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
CHAPTER 8: EAR INFECTION TREATMENT MARKET, BY REGION
- 8.1. Overview
- 8.1.1. Market size and forecast By Region
- 8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Infection
- 8.2.3. Market size and forecast, by Pathogen
- 8.2.4. Market size and forecast, by Treatment
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
- 8.2.6.1. U.S.
- 8.2.6.1.1. Market size and forecast, by Infection
- 8.2.6.1.2. Market size and forecast, by Pathogen
- 8.2.6.1.3. Market size and forecast, by Treatment
- 8.2.6.1.4. Market size and forecast, by End User
- 8.2.6.2. Canada
- 8.2.6.2.1. Market size and forecast, by Infection
- 8.2.6.2.2. Market size and forecast, by Pathogen
- 8.2.6.2.3. Market size and forecast, by Treatment
- 8.2.6.2.4. Market size and forecast, by End User
- 8.2.6.3. Mexico
- 8.2.6.3.1. Market size and forecast, by Infection
- 8.2.6.3.2. Market size and forecast, by Pathogen
- 8.2.6.3.3. Market size and forecast, by Treatment
- 8.2.6.3.4. Market size and forecast, by End User
- 8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Infection
- 8.3.3. Market size and forecast, by Pathogen
- 8.3.4. Market size and forecast, by Treatment
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
- 8.3.6.1. Germany
- 8.3.6.1.1. Market size and forecast, by Infection
- 8.3.6.1.2. Market size and forecast, by Pathogen
- 8.3.6.1.3. Market size and forecast, by Treatment
- 8.3.6.1.4. Market size and forecast, by End User
- 8.3.6.2. France
- 8.3.6.2.1. Market size and forecast, by Infection
- 8.3.6.2.2. Market size and forecast, by Pathogen
- 8.3.6.2.3. Market size and forecast, by Treatment
- 8.3.6.2.4. Market size and forecast, by End User
- 8.3.6.3. UK
- 8.3.6.3.1. Market size and forecast, by Infection
- 8.3.6.3.2. Market size and forecast, by Pathogen
- 8.3.6.3.3. Market size and forecast, by Treatment
- 8.3.6.3.4. Market size and forecast, by End User
- 8.3.6.4. Italy
- 8.3.6.4.1. Market size and forecast, by Infection
- 8.3.6.4.2. Market size and forecast, by Pathogen
- 8.3.6.4.3. Market size and forecast, by Treatment
- 8.3.6.4.4. Market size and forecast, by End User
- 8.3.6.5. Spain
- 8.3.6.5.1. Market size and forecast, by Infection
- 8.3.6.5.2. Market size and forecast, by Pathogen
- 8.3.6.5.3. Market size and forecast, by Treatment
- 8.3.6.5.4. Market size and forecast, by End User
- 8.3.6.6. Rest of Europe
- 8.3.6.6.1. Market size and forecast, by Infection
- 8.3.6.6.2. Market size and forecast, by Pathogen
- 8.3.6.6.3. Market size and forecast, by Treatment
- 8.3.6.6.4. Market size and forecast, by End User
- 8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Infection
- 8.4.3. Market size and forecast, by Pathogen
- 8.4.4. Market size and forecast, by Treatment
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
- 8.4.6.1. Japan
- 8.4.6.1.1. Market size and forecast, by Infection
- 8.4.6.1.2. Market size and forecast, by Pathogen
- 8.4.6.1.3. Market size and forecast, by Treatment
- 8.4.6.1.4. Market size and forecast, by End User
- 8.4.6.2. China
- 8.4.6.2.1. Market size and forecast, by Infection
- 8.4.6.2.2. Market size and forecast, by Pathogen
- 8.4.6.2.3. Market size and forecast, by Treatment
- 8.4.6.2.4. Market size and forecast, by End User
- 8.4.6.3. Australia
- 8.4.6.3.1. Market size and forecast, by Infection
- 8.4.6.3.2. Market size and forecast, by Pathogen
- 8.4.6.3.3. Market size and forecast, by Treatment
- 8.4.6.3.4. Market size and forecast, by End User
- 8.4.6.4. India
- 8.4.6.4.1. Market size and forecast, by Infection
- 8.4.6.4.2. Market size and forecast, by Pathogen
- 8.4.6.4.3. Market size and forecast, by Treatment
- 8.4.6.4.4. Market size and forecast, by End User
- 8.4.6.5. South Korea
- 8.4.6.5.1. Market size and forecast, by Infection
- 8.4.6.5.2. Market size and forecast, by Pathogen
- 8.4.6.5.3. Market size and forecast, by Treatment
- 8.4.6.5.4. Market size and forecast, by End User
- 8.4.6.6. Rest of Asia-Pacific
- 8.4.6.6.1. Market size and forecast, by Infection
- 8.4.6.6.2. Market size and forecast, by Pathogen
- 8.4.6.6.3. Market size and forecast, by Treatment
- 8.4.6.6.4. Market size and forecast, by End User
- 8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Infection
- 8.5.3. Market size and forecast, by Pathogen
- 8.5.4. Market size and forecast, by Treatment
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
- 8.5.6.1. Brazil
- 8.5.6.1.1. Market size and forecast, by Infection
- 8.5.6.1.2. Market size and forecast, by Pathogen
- 8.5.6.1.3. Market size and forecast, by Treatment
- 8.5.6.1.4. Market size and forecast, by End User
- 8.5.6.2. Saudi Arabia
- 8.5.6.2.1. Market size and forecast, by Infection
- 8.5.6.2.2. Market size and forecast, by Pathogen
- 8.5.6.2.3. Market size and forecast, by Treatment
- 8.5.6.2.4. Market size and forecast, by End User
- 8.5.6.3. South Africa
- 8.5.6.3.1. Market size and forecast, by Infection
- 8.5.6.3.2. Market size and forecast, by Pathogen
- 8.5.6.3.3. Market size and forecast, by Treatment
- 8.5.6.3.4. Market size and forecast, by End User
- 8.5.6.4. Rest of LAMEA
- 8.5.6.4.1. Market size and forecast, by Infection
- 8.5.6.4.2. Market size and forecast, by Pathogen
- 8.5.6.4.3. Market size and forecast, by Treatment
- 8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
- 10.1. WraSer pharmaceutical
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Key strategic moves and developments
- 10.2. Torque Pharmaceuticals Pvt. Ltd.
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.3. Glenmark Pharmaceuticals Limited
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
- 10.4. Candela Healthcare Private Limited
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.5. Leeford Healthcare Limited
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.6. FDC Limited
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
- 10.7. Torrent Pharmaceuticals Ltd.
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.8. Novartis AG
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Business performance
- 10.9. Cipla Ltd.
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
